Search Khaleej Dailies

Sunday, August 26, 2012

Key results from new tiotropium studies in COPD and asthma to be presented at ERS 2012


INGELHEIM,Germany - Sunday, August 26th 2012 [ME NewsWire]

    First Phase III exacerbation and lung function data for tiotropium via the Respimat® inhaler in asthmaA
    New Phase II data on combination of tiotropium and olodaterol administered by Respimat® in COPDB

(BUSINESS WIRE)-- New data to be presented at the Annual Congress of the European Respiratory Society (ERS 2012), in Vienna, Austria, will shed light on the current and potential future role of tiotropium, the first once-daily long-acting inhaled anticholinergic for patients with Chronic Obstructive Pulmonary Disease (COPD).

Highlights from the accepted abstracts include the first Phase III exacerbation and lung function data for Boehringer Ingelheim’s and Pfizer’s tiotropium in asthma. These results derive from two replicate studies evaluating the efficacy of once-daily tiotropium administered by the Respimat® Soft MistTM Inhaler (SMI) in patients with severe asthma who remain symptomatic on at least ICSC/LABAD. The data are relevant since a significant proportion of patients with asthma remain symptomatic despite current treatment options and may have asthma exacerbations.1

A further presentation will focus on results from a Phase II study that investigates the potential of a future fixed-dose combination (FDC) of tiotropium and Boehringer Ingelheim’s once-daily LABA olodaterol in patients with COPD. This Phase II trial was looking at the impact of different doses of tiotropium and olodaterol as a free combination on lung function, both administered individually by the Respimat® SMI. Boehringer Ingelheim has already started to evaluate the tiotropium and olodaterol FDC in the TOviTOTM Phase III clinical trial programme.

In addition, a new analysis of the four year UPLIFTTM data will be presented. This study evaluated the effect of tiotropium (18 µg via HandiHaler®) in low risk patients based on the newly defined patient groups in the updated report of the Global Initiative for Chronic Obstructive Lung Disease (GOLD). It will further add to the wealth of data for tiotropium in COPD, which has now been investigated in 175 clinical trials in COPD.

The ERS congress is the largest respiratory meeting in the World, with attendance from more than 100 countries.2 All tiotropium abstracts can be accessed through the ERS website, http://www.erscongress2012.org/.

Asthma

Topic
         

Lead Author
         

Presentation details
   

Exacerbation data from two Phase III studies evaluating efficacy of once-daily tiotropium in severe asthma patients symptomatic despite ICS/LABA therapy
         

HAM Kerstjens
         

Poster discussion

Monday 3rd September

08.30-10.30
   

Lung function data from two Phase III studies evaluating efficacy of once- daily tiotropium in severe asthma patients symptomatic despite ICS/LABA therapy
         

HAM Kerstjens
         

Poster session

Monday 3rd September

12.50-14.40
   
                             

COPD

Topic
         

Lead Author
         

Presentation details
   

Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPD
         

R Aalbers
         

Poster discussion

Monday 3rd September

14.45-16.45
   

Effectiveness of tiotropium in low-risk patients according to new GOLD severity grading
         

D Halpin
         

Poster session

Monday 3rd September

12.50-14.40
   
                             

– Ends –

Please click on the link below for ‘Notes to Editors’:

www.boehringer-ingelheim.com/news/news_releases/press_releases/2012/27_august_2012_tiotropium.html

References

1. Rabe, KF, Vermeire, PA, Soriano, JB, et al Clinical management of asthma in 1999: the Asthma Insights in Europe (AIRE) study. Eur Respir J 2000; 16, 802-807

2. http://www.erscongress2012.org/ (accessed 07/06/2012)

A Tiotropium is not licensed for the treatment of asthma

B The combination of tiotropium and olodaterol is not licensed for the treatment of COPD

C Inhaled corticosteroids

D Long-acting beta2-agonists

Contacts

Boehringer Ingelheim

Corporate Communications

Media + PR

Sebastian Wachtarz

55216 Ingelheim/Germany

Phone: +49 6132 – 77 3519

Fax: +49 6132 – 77 6601

Email: press@boehringer-ingelheim.com



More information

www.boehringer-ingelheim.com

1 comment:

  1. A lot of people suffering from COPD disease. Tobacco smoking is the most common cause of COPD, with factors such as air pollution and genetics playing a smaller role. find about copd treatment as early as possible.

    ReplyDelete